HEAD & NECK CANCERS

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

Evidence suggests that extranodal extension on radiological imaging is a negative prognostic factor in head and neck cancer, but diagnostic criteria and terminology have been unclear.

Camrelizumab increased the 3-year event-free survival rate vs standard of care from 77.3% to 86.9%, translating to a 44% reduced risk of death or relapse in patients with nasopharyngeal carcinoma.

Neoadjuvant chemotherapy prior to surgery and postoperative radiation therapy could improve organ preservation in patients with T3 and T4a nasal and paranasal sinus squamous cell carcinoma.

Christina Henson, MD, discusses how new guidelines for head and neck cancer imaging could change dynamics for physicians and patients.

Elizabeth Franzmann, MD, discusses findings of a study exploring a novel method of testing recurrence of head and neck cancer.

Christina Henson, MD, discussed proposed guidelines for head and neck cancer imaging to improve patient outcomes and consistency across practices.

With this designation, the sponsor of APG-157 is eligible for more frequent interaction with the FDA, facilitating faster drug development and review for this neoadjuvant head and neck cancer therapy.

A phase 2 trial will assess BRG01 for the treatment of patients with relapsed/metastatic EBV-positive nasopharyngeal carcinoma.

Christina Henson, MD, discusses unmet needs among patients with head and neck cancer.

Gedeptin, a novel gene therapy, is entering phase 2 clinical trials to evaluate its efficacy in treating recurrent head and neck cancer.

Replacing fluorouracil with paclitaxel in combination with pembrolizumab and carboplatin appears to be efficacious and tolerable in patients with recurrent/metastatic head and neck cancer.

The FDA has granted a fast track designation to ozuriftamab vedotin for treating recurrent/metastatic head and neck cancer that progressed after prior therapies.

A new immunotherapy combination of eftilagimod alpha and pembrolizumab shows promise in treating head and neck squamous cell carcinoma, even in patients with low PD-L1 expression.

In an interview, Cesar Augusto Perez, MD, delved into the findings from a phase 2 study evaluating petosemtamab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

The 2-year investigator-assessed event-free survival rate in the intent-to-treat population of patients with high-risk head and neck squamous cell carcinoma was 67.4% with atezolizumab.

Cesar Augusto Perez, MD, discusses the efficacy data reported in a phase 2 study of petosemtamab plus pembrolizumab for the first-line treatment of patients with recurrent/metastatic head and neck squamous cell carcinoma.

Frontline treatment with petosemtamab and pembrolizumab produced early clinical efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

According to findings from the phase 3 ESOPEC trial, perioperative chemotherapy given with FLOT improved overall survival in resectable esophageal cancer.

In a phase 1/2 trial of NT219 with cetuximab in patients with squamous cell carcinoma of the head and neck, safety and tolerability responses were encouraging.

The phase 2 VERSATILE-002 trial evaluating Versamune HPV with pembrolizumab met its primary end point in patients with first-line recurrent metastatic head and neck squamous cell cancer.

9MW2821 was granted an orphan drug designation from the FDA and is being evaluated for the potential treatment of esophageal cancer, as well as other cancers.

Early research suggests setanaxib combined with pembrolizumab may be a promising treatment for patients with squamous cell carcinoma of the head and neck.

In an interview with Targeted Oncology for Head and Neck Cancer Awareness Month, Noel Laudi, MD, MRCP, discussed the link between human papillomavirus infection and head and neck cancers.

The FDA’s fast track designation of LYT-200 in this population is supported by an ongoing phase 1/2 clinical trial.